CureVac Converts To Modified mRNA And Stock Soars
New CEO Incoming
Executive Summary
CureVac, formerly a cheerleader of the unmodified mRNA approach, is embracing the modified version for its vaccine portfolio, a move that has gone down well with the investment community.